MARK2 and coronary artery disorder: For these reasons, PAR1 antagonists have been studied for use as antithrombotic agents [72,73,74,75,76], and in 2014 vorapaxar (ZontivityTM) was approved by the FDA for coronary artery disease [77,78,79].